Ziopharm Oncology (ZIOP) Misses Q3 EPS by 34c

Ziopharm Oncology (NASDAQ: ZIOP) reported Q3 EPS of ($0.43), $0.34 worse than the analyst estimate of ($0.09).

“Our company took dramatic steps forward in the past quarter, in particular with our TCR-T platform,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. “The NCI advanced the TCR program using our Sleeping Beauty platform into a phase 2 trial and our new agreement with MD Anderson accelerates expansion of our TCR library and sets the foundation for two new clinical trials to be conducted there by Ziopharm. Our confidence surges as we have partnered with these leading institutions in tackling the massive, untapped market in solid tumors.”

For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Akari Therapeutics shares preclinical data for AKTX-101 in urothelial cancer
• 374Water Inc (SCWO) Misses Q2 EPS by 15c